Our results indicate that the release of DAMPs such as HMGB1 from Ad-TK infected tumor cells is required for the efficacy of Ad-TK + Ad-Flt3L mediated immunotherapy (Candolfi et al., 2009; Curtin et al., 2009). Here, HMGB1 is linked to neoplasm.